ORTHOPEDIATRICS CORP — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Q2 2026 revenue hit $70.5M (up 15% YoY from $61.1M), surpassing $70M for first time; company raised full-year 2026 guidance to $265–269M (from $263–267M), representing 12–14% growth. Adjusted EBITDA improved to $6.8M (Q2 2026) vs. $4.1M (Q2 2025); free cash flow usage improved 78% to $3.1M. Trauma & Deformity grew 26%; Scoliosis declined 9%. Company expects to achieve breakeven free cash flow in 2026. Announced exclusive distribution deal with OSSIO for bio-integrative fixation technology.
Why this rating
Record revenue and guidance raise with improving profitability/cash flow are meaningful for ~$362M market-cap company; however, still posting net losses ($7.2M Q2) and absolute dollar improvements modest relative to size. Guidance raise of ~$2M midpoint is ~0.6% of market cap—real but not transformational.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.